In preclinical models, anti-CTLA-4 antibodies cause tumor rejection by engaging Fc receptors which are critical for antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis (ADCP). The gene discussed is CTLA4; the disease is neoplasm.